UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

BET inhibitors: a novel epigenetic approach

Annals of oncology, 2017-08, Vol.28 (8), p.1776-1787

2017

Volltextzugriff (PDF)

588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies

European journal of cancer (1990), 2012-11, Vol.48, p.180-180

2012

Volltextzugriff (PDF)

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Annals of oncology, 2016-03, Vol.27 (3), p.526-532

2016

Volltextzugriff (PDF)

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

Annals of oncology, 2018-05, Vol.29 (5), p.1304-1311

2018

Volltextzugriff (PDF)

1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

Annals of oncology, 2023-10, Vol.34, p.S625-S626

2023

Volltextzugriff (PDF)

Vascular disrupting agents

Journal of cellular biochemistry, 2006-11, Vol.99 (4), p.1021-1039

2006

Volltextzugriff (PDF)

388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors

European journal of cancer supplements, 2010, Vol.8 (7), p.123-123

2010

Volltextzugriff (PDF)

383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics

European journal of cancer supplements, 2010, Vol.8 (7), p.121-122

2010

Volltextzugriff (PDF)

189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

European journal of cancer supplements, 2010, Vol.8 (7), p.64-64

2010

Volltextzugriff (PDF)

468 POSTER The role of thymidine kinase and thymidylate synthase in the response of tumor cells to the suicide prodrug 2′-F-ara-deoxyuridine

European journal of cancer supplements, 2008, Vol.6 (12), p.150-150

2008

Volltextzugriff (PDF)

Phase I, Open-Label, Randomized, Crossover Study Evaluating the Effects of Linifanib on Qtc Intervals in Patients with Solid Tumors

Annals of oncology, 2012-09, Vol.23, p.ix173

2012

Volltextzugriff (PDF)

Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy

Annals of oncology, 2012-09, Vol.23, p.ix170

2012

Volltextzugriff (PDF)

507 - Phase I, Open-Label, Randomized, Crossover Study Evaluating the Effects of Linifanib on Qtc Intervals in Patients with Solid Tumors

Annals of oncology, 2012-09, Vol.23, p.ix173-ix173

2012

Volltextzugriff (PDF)

497P - Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy

Annals of oncology, 2012-09, Vol.23, p.ix170-ix170

2012

Volltextzugriff (PDF)

1205 A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours

European journal of cancer supplements, 2009, Vol.7 (2), p.122-122

2009

Volltextzugriff (PDF)

216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors

European journal of cancer supplements, 2008, Vol.6 (12), p.68-69

2008

Volltextzugriff (PDF)

Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib

Annals of oncology, 2012-09, Vol.23, p.ix362

2012

Volltextzugriff (PDF)

1111PD - Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib

Annals of oncology, 2012-09, Vol.23, p.ix362-ix362

2012

Volltextzugriff (PDF)

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

Annals of oncology, 2012-09, Vol.23, p.ix158

2012

Volltextzugriff (PDF)

Phase 1/2 Study of Oral Rucaparib: Updated Phase 1 and Preliminary Phase 2 Results

Annals of oncology, 2014-09, Vol.25, p.iv307

2014

Volltextzugriff (PDF)

882PDPHASE 1/2 STUDY OF ORAL RUCAPARIB: UPDATED PHASE 1 AND PRELIMINARY PHASE 2 RESULTS

Annals of oncology, 2014-09, Vol.25 (suppl_4), p.iv307-iv308

2014

Volltextzugriff (PDF)

355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449

European journal of cancer supplements, 2008, Vol.6 (12), p.112-113

2008

Volltextzugriff (PDF)

A Phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a Phase I accelerated titration 2B design

Investigational new drugs, 2003-02, Vol.21 (1), p.63-74

2003

Volltextzugriff (PDF)

644 POSTER The novel oral taxane BMS275183 has a favorable activity and toxicity profile in a twice weekly schedule; Preliminary findings from an extended phase I trial

European journal of cancer supplements, 2006-11, Vol.4 (12), p.194-194

2006

Volltextzugriff (PDF)

501 Prospective UGT1A1 genotyping in a phase I study of safety and pharmacokinetics of liposome encapsulated SN-38 (LE-SN38)

European journal of cancer supplements, 2004-09, Vol.2 (8), p.153-153

2004

Volltextzugriff (PDF)

1 – 25 von 41

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(40)
Mit Volltextzugriff
(39)

Publikationsform

Sprache

Englisch
(41)

Erscheinungsjahr

n.n

Thema

Science & Technology
(12)
Physics
(9)
Hematology, Oncology And Palliative Medicine
(8)
Physical Sciences
(7)
Nuclear Experiment
(6)
Physics, Nuclear
(6)
Life Sciences & Biomedicine
(5)
Humans
(4)
Neoplasms - Drug Therapy
(4)
Oncology
(4)
Adult
(3)
Aged
(3)
Dose-Response Relationship, Drug
(3)
Female
(3)
Física
(3)
Half-Life
(3)
Male
(3)
Maximum Tolerated Dose
(3)
Middle Aged
(3)
Neutrons
(3)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

BET inhibitors: a novel epigenetic approach

588 A First-in-patient Phase I Study of the Novel Gamma Secretase Inhibitor PF-03084014 in Patients with Advanced Solid Tumor Malignancies

A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors

Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors

1029P Dazostinag (TAK-676) alone and in combination with pembrolizumab (pembro) in patients (pts) with advanced or metastatic solid tumors: Preliminary safety, PK/PD, and anti-tumor activity in a phase I dose escalation study supporting a recommended dose for expansion (RDE)

Vascular disrupting agents

388 Imetelstat sodium (GRN163L), a telomerase inhibitor: tolerability, pharmacokinetics and pharmacodynamic activity using an intermittent once every four weeks dosing schedule in patients with advanced solid tumors

383 First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics

189 Preclinical activity of the poly (ADP-ribose) polymerase (PARP) inhibitor ABT-888 in combination with irinotecan in ovarian and triple negative breast cancers

468 POSTER The role of thymidine kinase and thymidylate synthase in the response of tumor cells to the suicide prodrug 2′-F-ara-deoxyuridine

Phase I, Open-Label, Randomized, Crossover Study Evaluating the Effects of Linifanib on Qtc Intervals in Patients with Solid Tumors

Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy

507 - Phase I, Open-Label, Randomized, Crossover Study Evaluating the Effects of Linifanib on Qtc Intervals in Patients with Solid Tumors

497P - Dose-Escalation Phase I Study of Cabazitaxel (CBZ) + Gemcitabine (GEM) in Patients (PTS) with Metastatic or Unresectable Advanced Solid Malignancy

1205 A first-in-human Phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumours

216 POSTER A phase I dose-escalation study of the safety, pharmacokinetics and pharmacodynamics of XL765, a novel inhibitor of PI3K and mTOR, administered orally to patients with solid tumors

Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib

1111PD - Expanded Access Study of Advanced Bcc Patients Treated with the Hedgehog-Pathway Inhibitor Vismodegib

Multicenter, Dose-Escalation Study of the Investigational Drug Tak-733, An Oral Mek inhibitor, in Patients (PTS) with Advanced Solid Tumors: Preliminary Phase 1 Results

Phase 1/2 Study of Oral Rucaparib: Updated Phase 1 and Preliminary Phase 2 Results

882PDPHASE 1/2 STUDY OF ORAL RUCAPARIB: UPDATED PHASE 1 AND PRELIMINARY PHASE 2 RESULTS

355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449

A Phase I clinical trial of spicamycin derivative KRN5500 (NSC 650426) using a Phase I accelerated titration 2B design

644 POSTER The novel oral taxane BMS275183 has a favorable activity and toxicity profile in a twice weekly schedule; Preliminary findings from an extended phase I trial

501 Prospective UGT1A1 genotyping in a phase I study of safety and pharmacokinetics of liposome encapsulated SN-38 (LE-SN38)

Suchergebnisse filtern